Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-R-DHAP in R/R DLBCL
NCT05966233Phase 2Withdrawn
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jan 2024
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Planned start Jan 2024; status: withdrawn.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05966233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966233.